Imaging-guided nanomedicine development

Aurora Bernal; Claudia Calcagno; Willem J.M. Mulder; Carlos Pérez-Medina

doi:10.1016/j.cbpa.2021.01.014

Imaging-guided nanomedicine development

Aurora Bernal, Claudia Calcagno, Willem J.M. Mulder, Carlos Pérez-Medina (Corresponding author)

Research output: Contribution to journal › Review article › Academic › peer-review

5 Citations (Scopus)

Abstract

Nanomedicine research is an active field that produces thousands of studies every year. However, translation of nanotherapeutics to the clinic has yet to catch up with such a vast output. In recent years, the need to better understand nanomedicines’ in vivo behavior has been identified as one of the major challenges for efficient clinical translation. In this context, noninvasive imaging offers attractive solutions to provide valuable information about nanomedicine biodistribution, pharmacokinetics, stability, or therapeutic efficacy. Here, we review the latest imaging approaches used in the development of therapeutic nanomedicines, discuss why these strategies bring added value along the translational pipeline, and give a perspective on future advances in the field.

Original language	English
Pages (from-to)	78-85
Number of pages	8
Journal	Current Opinion in Chemical Biology
Volume	63
DOIs	https://doi.org/10.1016/j.cbpa.2021.01.014
Publication status	Published - Aug 2021

Bibliographical note

Funding Information:
The work of AB and CPM is supported by Comunidad Aut?noma de Madrid's Programa de Atracci?n de Talento (2018 T1/BMD10758). WJMM and CPM are supported by National Institutes of Health (NIH) grant R01 CA220234. WJMM is also supported by NIH grants R01 HL144072, P01 HL131478, and NWO/ZonMW Vici 91818622.

Access to Document

10.1016/j.cbpa.2021.01.014

Cite this

@article{1c0772f49d7b422ba3ac3a439780916d,

title = "Imaging-guided nanomedicine development",

abstract = "Nanomedicine research is an active field that produces thousands of studies every year. However, translation of nanotherapeutics to the clinic has yet to catch up with such a vast output. In recent years, the need to better understand nanomedicines{\textquoteright} in vivo behavior has been identified as one of the major challenges for efficient clinical translation. In this context, noninvasive imaging offers attractive solutions to provide valuable information about nanomedicine biodistribution, pharmacokinetics, stability, or therapeutic efficacy. Here, we review the latest imaging approaches used in the development of therapeutic nanomedicines, discuss why these strategies bring added value along the translational pipeline, and give a perspective on future advances in the field.",

author = "Aurora Bernal and Claudia Calcagno and Mulder, {Willem J.M.} and Carlos P{\'e}rez-Medina",

note = "Funding Information: The work of AB and CPM is supported by Comunidad Aut?noma de Madrid's Programa de Atracci?n de Talento (2018 T1/BMD10758). WJMM and CPM are supported by National Institutes of Health (NIH) grant R01 CA220234. WJMM is also supported by NIH grants R01 HL144072, P01 HL131478, and NWO/ZonMW Vici 91818622. ",

year = "2021",

month = aug,

doi = "10.1016/j.cbpa.2021.01.014",

language = "English",

volume = "63",

pages = "78--85",

journal = "Current Opinion in Chemical Biology",

issn = "1367-5931",

publisher = "Elsevier",

}

TY - JOUR

T1 - Imaging-guided nanomedicine development

AU - Bernal, Aurora

AU - Calcagno, Claudia

AU - Mulder, Willem J.M.

AU - Pérez-Medina, Carlos

N1 - Funding Information: The work of AB and CPM is supported by Comunidad Aut?noma de Madrid's Programa de Atracci?n de Talento (2018 T1/BMD10758). WJMM and CPM are supported by National Institutes of Health (NIH) grant R01 CA220234. WJMM is also supported by NIH grants R01 HL144072, P01 HL131478, and NWO/ZonMW Vici 91818622.

PY - 2021/8

Y1 - 2021/8

N2 - Nanomedicine research is an active field that produces thousands of studies every year. However, translation of nanotherapeutics to the clinic has yet to catch up with such a vast output. In recent years, the need to better understand nanomedicines’ in vivo behavior has been identified as one of the major challenges for efficient clinical translation. In this context, noninvasive imaging offers attractive solutions to provide valuable information about nanomedicine biodistribution, pharmacokinetics, stability, or therapeutic efficacy. Here, we review the latest imaging approaches used in the development of therapeutic nanomedicines, discuss why these strategies bring added value along the translational pipeline, and give a perspective on future advances in the field.

AB - Nanomedicine research is an active field that produces thousands of studies every year. However, translation of nanotherapeutics to the clinic has yet to catch up with such a vast output. In recent years, the need to better understand nanomedicines’ in vivo behavior has been identified as one of the major challenges for efficient clinical translation. In this context, noninvasive imaging offers attractive solutions to provide valuable information about nanomedicine biodistribution, pharmacokinetics, stability, or therapeutic efficacy. Here, we review the latest imaging approaches used in the development of therapeutic nanomedicines, discuss why these strategies bring added value along the translational pipeline, and give a perspective on future advances in the field.

UR - http://www.scopus.com/inward/record.url?scp=85102450976&partnerID=8YFLogxK

U2 - 10.1016/j.cbpa.2021.01.014

DO - 10.1016/j.cbpa.2021.01.014

M3 - Review article

C2 - 33735814

AN - SCOPUS:85102450976

VL - 63

SP - 78

EP - 85

JO - Current Opinion in Chemical Biology

JF - Current Opinion in Chemical Biology

SN - 1367-5931

ER -

Imaging-guided nanomedicine development

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this